CRVS
Corvus·NASDAQ
--
--(--)
--
--(--)
Signals Analysis
Bullish signal 2
Bearish signal 0
Stock Price Surged Significantly
Consensus Rating "Buy"
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CRVS
Corvus Pharmaceuticals, Inc.
A clinical-stage biopharmaceutical company that developing immuno-oncology therapies to enhance the immune systems of patients with solid tumors and cancer
901 Gateway Boulevard, Third Floor, South San Francisco, CA 94080
--
Corvus Pharmaceuticals, Inc., was incorporated in Delaware on January 27, 2014. The company is a clinical-stage biopharmaceutical company that is developing product candidates for proteins that are critical to immune cell function. Its lead drug candidate, soquelitinib, is designed to inhibit ITK and is currently being evaluated in clinical trials for conditions including T-cell lymphoma and atopic dermatitis. The company's strategy focuses on applying its immunology expertise to multiple disease areas with significant unmet medical needs.
Company Financials
EPS
CRVS has released its 2025 Q3 earnings. EPS was reported at -0.12, versus the expected -0.13, beating expectations. The chart below visualizes how CRVS has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
